Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Retinitis Pigmentosa – Epidemiology – Epidemiology – Retinitis Pigmentosa – Mature Markets
Clarivate Epidemiology’s coverage of retinitis pigmentosa comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France,…
Diabetic Macular Edema / Diabetic Retinopathy – Current Treatment – Current Treatment: Physician Insights – Diabetic Macular Edema / Diabetic Retinopathy (US)
Diabetic macular edema (DME) is a complication of diabetic retinopathy (DR) derived from chronically high blood sugar levels and resulting in vision loss and blindness if left untreated. The VEGF…
Dry and Wet Age-Related Macular Degeneration – Access & Reimbursement – Access & Reimbursement – Age-Related Macular Degeneration (US)
The age-related macular degeneration (AMD) therapy market in the United States is unique because the market penetration of approved branded therapies—Roche / Genentech’s Lucentis, Regeneron’s…
Dry and Wet Age-Related Macular Degeneration – Current Treatment – Treatment Algorithms: Claims Data Analysis – Dry and Wet Age-Related Macular Degeneration (US)
The treatment of wet AMD in the United States has been mainly dominated by three anti-VEGF therapies: Roche / Genentech’s off-label Avastin, Roche / Genentech’s Lucentis, and Regeneron’s…
Dry and Wet Age-Related Macular Degeneration – Special Topics – Special Topics: Gene Therapies in Ophthalmology (US)
The wet age-related macular degeneration (AMD) market in the United States is replete with intravitreal (IVT) therapies—including Regeneron’s Eylea, Roche / Genentech’s Lucentis and Vabysmo,…
